NEW YORK (GenomeWeb) – Advanced Biological Laboratories announced it has granted Abbott non-exclusive rights to sell its HIV genotypic data analysis software suite.
Abbott will market ABL's data analysis software to its customers within the US, the largest market in the world for HIV genotyping for diagnostic use and in clinical trials. ABL, based in Luxembourg, is aiming to expand the presence and use of its products in the US market, CEO Chalom Sayada said in a statement.
Abbot is a leading player in the HIV genotyping market with its RealTime HIV-1 test. The diagnostic gauges levels of all viral groups and subtypes and is readily used in studies run by entities such as AIDS Clinical Trials Group and International Maternal Pediatric Adolescent AIDS Clinical Trials Group.